Learn, Analyse & Invest
only with
only with
+91
Download Orca
Sudarshan Pharma Industries Ltd.
Sudarshan Pharma Ind
₹ 0.00
0.00 (0.00)%
NSE
BSE
Healthcare
Small-cap - With a market cap of ₹7.28 Cr.
| EX-Date | Purpose |
|---|---|
| 26 05 2023 | Final Dividend & Audited Results |
| 21 07 2023 | Increase in Authorised Capital & Final Dividend & Employees Stock Option Plan Inter-alia, to consider and approve the following business: 1. To recommend Final Dividend to the equity shareholders of the Company for the Financial Year 2022-2023. 2. To approve AGM Notice along with Annual Report 3. To fix up date, time and venue for annual general meeting; 4. To fix cut-off date for dispatch of annual report 5. To fix cut-off date for e-voting and to fix e-voting period 6. To fix record date for final dividend 7. Re-appointment of Managing Director of the Company. 8. Re-appointment of Joint Managing Director of the Company. 9. To consider and approve ESOP. 10. Appointment of Additional Director (Independent) 11. Increase in Authorized Share Capital 12. To approve related party transaction |
| 02 08 2023 | Inter-alia, to consider and approve the following business: 1. To acquire ?RATNA LIFESCIENCES PRIVATE LIMITED? (herein after referred as a Company) as the Wholly-Owned Subsidiary. 2. To incorporate a Subsidiary Company. |
| 18 08 2023 | Inter alia, to consider :- To give approval for incorporating a subsidiary company in the name and style of ?LIFESCIENCES CHEMICAL PRIVATE LIMITED?, in the state of Gujarat subject to approval of registrar of companies as may be required from time to time. |
| 10 11 2023 | Half Yearly Results & Employees Stock Option Plan |
| 28 03 2024 | Inter alia, to consider and approve:- 1. To give authority to appoint consultants and/or representatives. 2. To avail the credit facility. 3. To consider and discuss any other matter. |
| 30 09 2024 | Stock Split |
| 31 10 2024 | Half Yearly Results |
| 24 04 2025 | Audited Results |
| 19 06 2025 | Inter-alia, to consider and approve the proposal for raising further funds by way of issuance of equity shares or any other equity linked instruments or securities including convertible instruments, warrants, etc subject to applicable approvals. |
| 14 08 2025 | Quarterly Results |
| 18 10 2025 | Half Yearly Results |
| 28 01 2026 | Quarterly Results |
| 30 04 2026 | Audited Results |
News
